Search for


search for

CrossRef (0)
The Trend in the Development of Oncolytic Virus Therapy
Biomed Sci Letters 2019;25:201-210
Published online September 30, 2019;
© 2019 The Korean Society For Biomedical Laboratory Sciences.

Sun-Il Kwon,*

Department of Biomedical Laboratory Science, Deagu Health Science University, Daegu 41453, Korea
Correspondence to: Sun-Il Kwon. Department of Biomedical Laboratory Science, Deagu Health Science University, Youngsong-ro 15 (Taejeon-dong), Buk-ku, Daegu 41453, Korea.
Tel: +82-53-320-1302, Fax: +82-53-320-1450, e-mail:
Received July 5, 2019; Revised September 10, 2019; Accepted September 11, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The oncolytic viruses selectively infect and destroy cancer cells, not harming normal cells. The cancer cell materials released by oncolysis, like tumor antigens, stimulate host antitumor immune responses, which is a long-lasting antitumor immunity removing cancer cells in remote parts of the body by a systemic response. Oncolytic viruses armed with transgenes such as cytokines or other immune stimulating factors enhance the immune responses. The first oncolytic virus approved by US-FDA is Imlygic® targeting for melanoma. The oncolytic virus is considered as a revolutionary immunotherapy for tumors together with immune checkpoint inhibitors. A variety of oncolytic viruses are under research in the treatment of kidney cancer, liver cancer, breast cancer, and many others solid tumors. Clinical trials have shown promising results in different types of cancers. Here, we present a brief introduction of various aspects of oncolytic virus, and a review of the current status of oncolytic virus therapy development.
Keywords : Oncolytic virus, Cancer, Virus therapy, Transgenes, Combination therapy